Aspire Biopharma, Stock Net Income
| ASBP Stock | 0.09 0 2.16% |
Aspire BioPharma,'s fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Aspire Stock price.
| Last Reported | Projected for Next Year | ||
| Net Loss | -12.5 M | -11.9 M | |
| Net Loss | -12.5 M | -11.9 M | |
| Net Loss | (1.52) | (1.44) | |
| Net Income Per E B T | 0.90 | 0.80 |
Aspire BioPharma, Company Net Income Analysis
Aspire BioPharma,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Aspire BioPharma, Net Income | (12.54 M) |
Most of Aspire BioPharma,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aspire BioPharma, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aspire Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aspire BioPharma, is extremely important. It helps to project a fair market value of Aspire Stock properly, considering its historical fundamentals such as Net Income. Since Aspire BioPharma,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aspire BioPharma,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aspire BioPharma,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aspire Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Aspire BioPharma, reported net income of (12.54 Million). This is 103.67% lower than that of the Pharmaceuticals sector and 117.9% lower than that of the Health Care industry. The net income for all United States stocks is 102.2% higher than that of the company.
Aspire Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aspire BioPharma,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aspire BioPharma, could also be used in its relative valuation, which is a method of valuing Aspire BioPharma, by comparing valuation metrics of similar companies.Aspire BioPharma, is currently under evaluation in net income category among its peers.
Aspire Fundamentals
| Return On Asset | -1.95 | ||||
| Operating Margin | (590.16) % | ||||
| Current Valuation | 20.11 M | ||||
| Shares Outstanding | 138.45 M | ||||
| Shares Owned By Insiders | 20.70 % | ||||
| Shares Owned By Institutions | 2.91 % | ||||
| Number Of Shares Shorted | 9.88 M | ||||
| Price To Sales | 6,919 X | ||||
| Gross Profit | 884 | ||||
| EBITDA | (11.65 M) | ||||
| Net Income | (12.54 M) | ||||
| Total Debt | 1.27 M | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (2.05 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.64) X | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 13.43 M | ||||
| Total Asset | 147.99 K | ||||
| Retained Earnings | (2.78 M) | ||||
| Working Capital | (1.54 M) | ||||
| Net Asset | 147.99 K |
About Aspire BioPharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aspire BioPharma,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aspire BioPharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aspire BioPharma, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aspire BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aspire BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aspire BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with Aspire Stock
| 0.74 | NVO | Novo Nordisk AS Buyout Trend | PairCorr |
Moving against Aspire Stock
| 0.89 | MTC | MMTEC Inc Tech Boost | PairCorr |
| 0.86 | MRK | Merck Company Aggressive Push | PairCorr |
| 0.85 | JNJ | Johnson Johnson | PairCorr |
| 0.83 | GSK | GlaxoSmithKline PLC ADR | PairCorr |
| 0.82 | AZN | AstraZeneca PLC ADR | PairCorr |
The ability to find closely correlated positions to Aspire BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aspire BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aspire BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aspire BioPharma, to buy it.
The correlation of Aspire BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aspire BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aspire BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aspire BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Aspire Stock Analysis
When running Aspire BioPharma,'s price analysis, check to measure Aspire BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aspire BioPharma, is operating at the current time. Most of Aspire BioPharma,'s value examination focuses on studying past and present price action to predict the probability of Aspire BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aspire BioPharma,'s price. Additionally, you may evaluate how the addition of Aspire BioPharma, to your portfolios can decrease your overall portfolio volatility.